STOCK TITAN

Cryoport (CYRX) director Mandalam sells 23,214 shares, receives new stock awards

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Cryoport, Inc. director Ramkumar Mandalam reported a mix of equity grants and a stock sale. On June 5, 2026, he received 10,350 restricted stock rights that vest in full on June 5, 2027 and convert one-for-one into common shares, plus options for 16,077 shares at an exercise price of $15.70 expiring in 2033.

On June 8, 2026, he executed an open-market sale of 23,214 common shares at a weighted average price of $15.4412 per share, in multiple trades between $15.40 and $15.48. Following the sale, he directly holds 67,894 common shares.

Positive

  • None.

Negative

  • None.
Insider Mandalam Ramkumar
Role null
Sold 23,214 shs ($358K)
Type Security Shares Price Value
Sale Common Stock 23,214 $15.4412 $358K
Grant/Award Option (Right to Buy Common Stock) 16,077 $0.00 --
Grant/Award Common Stock 10,350 $0.00 --
Holdings After Transaction: Common Stock — 67,894 shares (Direct, null); Option (Right to Buy Common Stock) — 16,077 shares (Direct, null)
Footnotes (1)
  1. Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $15.48, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
Shares sold 23,214 shares Open-market sale of common stock on June 8, 2026
Sale price $15.4412 per share Weighted average sale price, trades between $15.40 and $15.48
Post-sale holdings 67,894 shares Common stock directly owned after June 8, 2026 sale
Restricted stock rights granted 10,350 units Grant on June 5, 2026, vesting in full on June 5, 2027
Options granted 16,077 options Grant on June 5, 2026, right to buy common stock
Option exercise price $15.70 per share Exercise price for 16,077 options expiring June 5, 2033
restricted stock rights financial
"Reflects grant of restricted stock rights that vest in full on June 5, 2027"
Restricted stock rights are ownership claims in company shares that come with limits on when or how they can be sold or transferred, often tied to time-based or performance conditions. For investors, these rights matter because they affect when insiders truly own or can monetize shares — influencing future share supply, executive incentives, and potential stock price pressure much like a savings account that only becomes withdrawable after meeting set conditions.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
options vest financial
"1/12th of the options vest on the 5th of the month for twelve months"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mandalam Ramkumar

(Last)(First)(Middle)
C/O CRYOPORT INC.
112 WESTWOOD PLACE, SUITE 350

(Street)
BRENTWOOD TENNESSEE 37027

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)06/05/2026A10,350A$0(1)91,108D
Common Stock06/08/2026S23,214D$15.4412(2)67,894D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (Right to Buy Common Stock)$15.706/05/2026A16,077 (3)06/05/2033Common Stock16,077$016,077D
Explanation of Responses:
1. Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $15.48, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
/s/ Ramkumar Mandalam06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Cryoport (CYRX) director Ramkumar Mandalam report?

He reported equity grants and a stock sale. On June 5, 2026, he received restricted stock rights and stock options, then on June 8, 2026, he sold 23,214 common shares in open-market transactions at a weighted average price of $15.4412 per share.

How many Cryoport (CYRX) shares did Ramkumar Mandalam sell and at what price?

He sold 23,214 shares of Cryoport common stock. The weighted average sale price was $15.4412 per share, with individual trades executed between $15.40 and $15.48, according to the disclosed transaction details and accompanying footnote explanation.

What stock awards did Ramkumar Mandalam receive from Cryoport (CYRX) on June 5, 2026?

He received 10,350 restricted stock rights and 16,077 stock options. The restricted stock rights vest in full on June 5, 2027, converting one-for-one into common shares, while the options have a $15.70 exercise price and vest monthly beginning July 5, 2026.

When do Ramkumar Mandalam’s restricted stock rights in Cryoport (CYRX) vest?

They vest in full on June 5, 2027. Once vested, these 10,350 restricted stock rights automatically convert into 10,350 shares of Cryoport common stock on a one-for-one basis, as described in the Form 4 footnote disclosure for the equity grant.

What are the terms of Ramkumar Mandalam’s Cryoport (CYRX) stock options granted in June 2026?

He was granted options for 16,077 shares at a $15.70 exercise price. One-twelfth of the options vest on the fifth of each month for twelve months starting July 5, 2026, and the options expire on June 5, 2033, if not exercised earlier.

How many Cryoport (CYRX) shares does Ramkumar Mandalam own after these transactions?

He directly holds 67,894 shares of Cryoport common stock after the June 8, 2026 sale. This post-transaction holding figure reflects his remaining direct ownership position as reported in the Form 4 following the open-market disposition of 23,214 shares.